PD-L1 expression levels are used as a biomarker to predict the clinical efficacy of immunotherapy, a meta-analysis indicated an association between PD-L1 expression and OS in ESCC (52). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.